Irbesartan remembered about possible cancerous ingredient NDEA


A third type of medication to treat high blood pressure and / or heart failure, not Valsartan or Losartan, has been withdrawn from the market because of too much of a potentially cancerous ingredient.

A batch of Irbesartan and seven batches of Irbesartan HCTZ, both manufactured in China by Zhejiang Huahai Pharmaceuticals, have been withdrawn by the company Prinston Pharmaceuticals, Solco Healthcare. Like the funeral parade of Valsartan and Losartan, which is remembered since July, the amount of N-nitrosodiethylamine (NDEA) exceeds the FDA's daily standards. The International Agency for Research on Cancer clbadifies the NDEA as a "probable human carcinogen".

The recall notice published by the FDA and published by the FDA advises patients to consult with their doctor or, at least, with their pharmacist about another form of treatment before returning any Irbesartan withdrawn from the market.

The lots removed are:

Digital access for only $ 0.99

For the most complete local coverage, subscribe today.

Irbesartan 300 mg, 90 units, lot No. 331B18009, expiration 2/2021.

Irbesartan HCTZ 300mg / 12.5mg, 30 units, lot numbers 327A18001 and 327A18001, due 03/2021.

Irbesartan HCTZ 300mg / 12.5mg, 90 units, lot numbers 327B18008 and 327B18009, due 03/2021.

Irbesartan HCTZ 150mg / 12.5mg, 30 units, lot numbers 325D18004 and 325D18005, due 03/2021.

Irbesartan HCTZ 150 mg / 12.5 mg, 90 units, Lot Nos. 325B18004, due 03/2021.

Consumers with questions should contact their pharmacist, doctor or email from Solco at [email protected]

Source link